Cargando…

Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) has the highest cancer mortality rate in the world, but currently there is no effective method of dynamic monitoring. Gene mutation is an important factor in tumorigenesis and can be detected using high-throughput sequencing technology. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yuanzhou, Chen, Qunqing, Zhang, Qiangzu, Li, Man, Li, Hui, Jia, Longfei, Huang, Yang, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506706/
https://www.ncbi.nlm.nih.gov/pubmed/34734005
http://dx.doi.org/10.21037/atm-21-4117
_version_ 1784581740656852992
author Wu, Yuanzhou
Chen, Qunqing
Zhang, Qiangzu
Li, Man
Li, Hui
Jia, Longfei
Huang, Yang
Zhang, Jian
author_facet Wu, Yuanzhou
Chen, Qunqing
Zhang, Qiangzu
Li, Man
Li, Hui
Jia, Longfei
Huang, Yang
Zhang, Jian
author_sort Wu, Yuanzhou
collection PubMed
description BACKGROUND: Non-small cell lung cancer (NSCLC) has the highest cancer mortality rate in the world, but currently there is no effective method of dynamic monitoring. Gene mutation is an important factor in tumorigenesis and can be detected using high-throughput sequencing technology. This study aimed to analyze the driving genes in the tumor of NSCLC patients by whole exon sequencing, and to compare and analyze the subclones of the tumor at different time points. METHODS: We collected 87 cases of NSCLC tumor tissues, para-cancer tissues, and peripheral blood samples for detecting cell-free DNAs (cfDNAs) from January 2016 to December 2018, and whole-exome sequencing was performed. The gene mutation map of NSCLC was drawn in detail by second-generation sequencing data analysis and new driver genes were found. In addition, we performed a subclonal analysis of tumors from different stages of the same patient to further describe the tumor heterogeneity. RESULTS: We found that the clonal analysis obtained by cfDNA detection was similar to the clonal analysis of the tissue samples, so real-time monitoring of tumor changes can be carried out through monitoring cfDNA. CONCLUSIONS: This study provides evidence for studying the gene mutation information of NSCLC and shows the importance of cfDNA in the analysis of tumor subcloning information.
format Online
Article
Text
id pubmed-8506706
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85067062021-11-02 Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer Wu, Yuanzhou Chen, Qunqing Zhang, Qiangzu Li, Man Li, Hui Jia, Longfei Huang, Yang Zhang, Jian Ann Transl Med Original Article BACKGROUND: Non-small cell lung cancer (NSCLC) has the highest cancer mortality rate in the world, but currently there is no effective method of dynamic monitoring. Gene mutation is an important factor in tumorigenesis and can be detected using high-throughput sequencing technology. This study aimed to analyze the driving genes in the tumor of NSCLC patients by whole exon sequencing, and to compare and analyze the subclones of the tumor at different time points. METHODS: We collected 87 cases of NSCLC tumor tissues, para-cancer tissues, and peripheral blood samples for detecting cell-free DNAs (cfDNAs) from January 2016 to December 2018, and whole-exome sequencing was performed. The gene mutation map of NSCLC was drawn in detail by second-generation sequencing data analysis and new driver genes were found. In addition, we performed a subclonal analysis of tumors from different stages of the same patient to further describe the tumor heterogeneity. RESULTS: We found that the clonal analysis obtained by cfDNA detection was similar to the clonal analysis of the tissue samples, so real-time monitoring of tumor changes can be carried out through monitoring cfDNA. CONCLUSIONS: This study provides evidence for studying the gene mutation information of NSCLC and shows the importance of cfDNA in the analysis of tumor subcloning information. AME Publishing Company 2021-09 /pmc/articles/PMC8506706/ /pubmed/34734005 http://dx.doi.org/10.21037/atm-21-4117 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wu, Yuanzhou
Chen, Qunqing
Zhang, Qiangzu
Li, Man
Li, Hui
Jia, Longfei
Huang, Yang
Zhang, Jian
Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer
title Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer
title_full Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer
title_fullStr Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer
title_full_unstemmed Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer
title_short Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer
title_sort analysis of whole-exome data of cfdna and the tumor tissue of non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506706/
https://www.ncbi.nlm.nih.gov/pubmed/34734005
http://dx.doi.org/10.21037/atm-21-4117
work_keys_str_mv AT wuyuanzhou analysisofwholeexomedataofcfdnaandthetumortissueofnonsmallcelllungcancer
AT chenqunqing analysisofwholeexomedataofcfdnaandthetumortissueofnonsmallcelllungcancer
AT zhangqiangzu analysisofwholeexomedataofcfdnaandthetumortissueofnonsmallcelllungcancer
AT liman analysisofwholeexomedataofcfdnaandthetumortissueofnonsmallcelllungcancer
AT lihui analysisofwholeexomedataofcfdnaandthetumortissueofnonsmallcelllungcancer
AT jialongfei analysisofwholeexomedataofcfdnaandthetumortissueofnonsmallcelllungcancer
AT huangyang analysisofwholeexomedataofcfdnaandthetumortissueofnonsmallcelllungcancer
AT zhangjian analysisofwholeexomedataofcfdnaandthetumortissueofnonsmallcelllungcancer